MarketBeat on MSN
Is Abbott's January pullback a good time to buy?
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making its stock look attractively valued. The move, driven ...
Q4 beat but Q1 guidance weak. Explore 2nm progress, AI PC targets, foundry yields, and 2030 margin goals. Click for this INTC ...
Jefferies pointed to an "attractive" risk-reward ratio for Meta at the current discount to Alphabet. ・The analyst also cited ...
Context for Citigroup after recent price moves Citigroup (C) has seen its share price slip about 1.8% in the last day and roughly 3.8% over the past week, resulting in a 6.6% decline over the past ...
Progressive may have a strong track record of growth, but there's a good reason why investors continue to bid the insurer's ...
Recent performance snapshot for Hut 8 Hut 8 (HUT) has caught investor attention after a mixed stretch, with a 6.5% decline ...
TSLA stock pulled back after a minor record high, but higher swing lows and recovered averages suggest the stock is ...
Lighter token LIT falls over 15% amid a broader market selloff, even as the perp DEX posts $2.25B in daily volume and ...
Intel Corporation faces soft Q1 guidance, margin compression, and a stretched 80x–91.6x forward PE as execution risks persist. Read why INTC stock is a sell.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results